Recalled U.S. drugs not licensed in Canada
Very unlikely that products tied to meningitis outbreak made it north of the border
Medicines bought or distributed in Canada are almost certainly not affected by the latest major U.S. recall by a pharmaceutical company tied to a deadly meningitis outbreak.
Massachusetts-based Ameridose LLC and the U.S. Food and Drug Administration announced Wednesday that the company is recalling all its unexpired drug products on the market, after federal inspectors said it must improve its sterility testing process.
Ameridose has the same founders as the New England Compounding Center, a specialty pharmacy whose steroid medications have been identified as the source of an outbreak of fungal meningitis that has killed 28 people in the United States.
Ameridose is not licensed to make any health products for the Canadian market, according to Health Canada's Drug Product Database. The agency said earlier this month that the same holds true for the New England Compounding Center, and added that it had no evidence that any of the Massachusetts firm's products were being imported, sold or used in Canada.
However, Health Canada still warned Canadians who travelled to the U.S. for medical treatment on or after May 21 to check to see whether their treatment facility might have received tainted products.
Ameridose makes mostly injection drug products like intravenous fluids, local anesthetics, IV painkillers and sedatives. A full list of the items it is recalling can be found on its website. The company was accused by a business customer earlier this year of failing to separate sterile and non-sterile products in its warehouse.
The U.S. Centers for Disease Control has a list of health-care facilities that received the potentially tainted steroids from NECC, but so far has no list of facilities that received products from Ameridose.
With files The Associated Press